PDI Therapeutics, Inc.

Avalon Ventures' Community Of Innovation (COI) offers life science experts an environment where entrepreneurial and scientific risks are encouraged and rewarded PDI Therapeutics Inc. develops immuno-oncology approach to cancer treatment by developing therapeutics that enhances the bodys ability to recognize and destroy tumor cells.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.coipharma.com/
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
11099 North Torrey Pines Suite 290, CA 92037
La Jolla
United States
Email
Contact Number

PDI Therapeutics Inc. develops immuno-oncology approach to cancer treatment by developing therapeutics that enhances the bodys ability to recognize and destroy tumor cells.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

PDI Therapeutics is named for protein disulfide isomerase. When overexpressed, this protein can help tumor cells avoid detection by the immune systems NK and T cells. PDI Therapeutics is developing antibody inhibitors to specific protein disulfide isomerases to unmask tumor cells so the immune system can recognize and destroy them. PDIs inhibitors could be used as a stand-alone therapy or in combination with other known immunotherapies, such as CAR-NK, that stimulate the immune system to recognize and eliminate solid tumors.

PDI Therapeutics recieved up to $10 Mn in Series A financing and R&D support from Avalon and GSK as well as R&D and mentoring support through COI Pharmaceuticals. GSK has the option to acquire each of the companies when a clinical candidate is identified. However, if GSK does not elect to exercise this option, Avalon will retain its ownership in the company, and the company will be free to enter into other strategic transactions.